Nika Pharmaceuticals, Inc. (NIKA) Markets Analysis and €8.5 Billion Projected Revenue

Rhea-AI Summary

Nika Pharmaceuticals (OTCQB: NIKA) has presented revenue projections for its ITV-1 HIV treatment across multiple markets with exclusive distribution agreements. The company projects total revenue of approximately €8.5 billion, with the majority (€7.9 billion) coming from Nigeria. Additional markets include UAE, Ukraine, Iraq, Jordan, and Syria, where NIKA will charge €1,980 per set of ITV-1, with two sets required per treatment.

In Ukraine, which has 158,803 registered HIV patients, NIKA projects potential revenue of €628 million. The combined markets of UAE, Iraq, Jordan, and Syria, with approximately 7,100 HIV patients, are expected to generate €28.1 million in revenue. The company emphasizes its dual mission of pursuing profits while providing affordable, life-saving treatments in regions with limited access to HIV care.

Positive

• Significant revenue potential of €8.5 billion across all markets
• Strong market presence in Nigeria with €7.9 billion projected revenue
• Additional €628 million potential revenue from Ukrainian market
• Strategic expansion into multiple markets through exclusive distribution agreements
• Clear pricing structure at €1,980 per set with defined treatment protocol

Negative

• Heavy revenue dependency on Nigerian market (93% of total projections)
• Small patient population in UAE, Iraq, Jordan, and Syria (only 7,100 combined)
• Political instability and war in Ukraine could affect market access and distribution
• Revenue projections are estimates and may not materialize

HENDERSON, Nev., May 19, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) presents projected revenue for each market with exclusive distribution agreement.

NIKA has previously reported an estimated potential €7.9 billion in revenue from its distribution agreement in Nigeria¹. With similar contact terms for the UAE, Ukraine, Iraq, Jordan, and Syria, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for one treatment. Although the UAE, Iraq, Jordan, and Syria have a low combined HIV numbers totaling around 7,100 people² with a projected revenue of around €28,116,000, AIDS/HIV has become a serious problem in the MENA region due to high mortality associated with the disease³. The ease of use, effectiveness, and affordability of NIKA’s treatment will help alleviate this issue.

The war in Ukraine has exacerbated the country’s issue with HIV due to low stocks of life-saving drugs and potential treatment disruption to nearly 78% of HIV patients on ART⁴. With 158,803 registered people living with HIV in Ukraine⁵, NIKA can potentially generate around €628 million and aid with this humanitarian crisis.

“Although the markets of Ukraine, UAE, Jordan, Syria, and Iraq are not as big as Nigeria, our mission is to not only chase profits, but also provide better and affordable life-saving drugs to those who have their lives at risk as they would otherwise not have access to treatment,” explained Dimitar Savov, CEO of NIKA.

About Nika Pharmaceuticals, Inc.

Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.

Forward-looking Statement:

This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “estimates,” “projects,” “intends,” “plan,” “can,” “will,” “would,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.

¹ See https://www.globenewswire.com/news-release/2024/07/18/2915494/0/en/Nika-Pharmaceuticals-Inc-NIKA-Signed-a-Distribution-Agreement-for-Nigeria.html
² Based on www.unaids.org estimates.
³ See https://pharmacophorejournal.com/e7AoOTeg1j
⁴ See https://www.unaids.org/en/War-Ukraine-special
⁵ See https://www.who.int/europe/news-room/19-12-2023-on-the-frontline-of-the-fight-against-hiv--ukraine-s-resilience-and-who-s-support#:~:text=In%20Ukraine%2C%20the%20Ministry%20of,Ukraine%20is%20currently%20158%20803

CONTACT Clifford Redekop, Secretary
COMPANY Nika Pharmaceuticals, Inc.
PHONE (702)-326-3615
EMAIL info@nikapharmaceuticals.com
WEB www.nikapharmaceuticals.com

FAQ

What is NIKA's projected total revenue across all markets?

Nika Pharmaceuticals projects approximately €8.5 billion in total revenue across all its markets, including Nigeria, UAE, Ukraine, Iraq, Jordan, and Syria.

How much does NIKA's ITV-1 HIV treatment cost per patient?

NIKA charges €1,980 per set of ITV-1, with two sets required for one complete treatment, totaling €3,960 per patient.

What is NIKA's projected revenue from the Ukrainian market?

NIKA projects potential revenue of approximately €628 million from Ukraine, where there are 158,803 registered people living with HIV.

How many HIV patients are in NIKA's Middle Eastern markets?

The combined HIV patient population in UAE, Iraq, Jordan, and Syria is approximately 7,100 people, with projected revenue of €28.116 million.

What percentage of NIKA's projected revenue comes from Nigeria?

Nigeria represents approximately 93% of NIKA's total projected revenue, with €7.9 billion out of the total €8.5 billion projection.